Scalper1 News
Biogen Idec (BIIB) stock slipped Wednesday after the company’s earnings guidance for 2014 fell far short of Wall Street estimates, but Q4 sales of its hot multiple sclerosis drug Tecfidera beat views. Biogen early Wednesday reported Q4 earnings and revenue that beat analyst expectations, with sales rising 39% from the year-earlier quarter to $2 billion and earnings per share minus items jumping 67% to $2.34. Analysts polled by Thomson Reuters had Scalper1 News
Scalper1 News